Amy Moss Trombly
Chief Executive Officer · Sonoma Pharmaceuticals, Inc.
- 2026
- Jul 10, 2026
- 2
Summary
Latest filing:
Amy Moss Trombly is Chief Executive Officer of Sonoma Pharmaceuticals, Inc. (SNOA). 2 SEC Form 4 filings on record, most recently on 10 July 2026.
Trading pattern
InsiderAlpha's records for Amy Moss Trombly go back to 2026: 2 primary Form 4 filings, an average of 2.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same sector
No other insider has filed at Amy Moss Trombly's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Emily M. Leproust - $100.57M in TWST purchases and sales in the last 12 months
- Catalyst4, Inc. - $98.71M in MPLT purchases and sales in the last 12 months
- Herriot Tabuteau - $97.80M in AXSM purchases and sales in the last 12 months
- Paul A. Mahon - $93.78M in UTHR purchases and sales in the last 12 months
- SUVRETTA CAPITAL MANAGEMENT, LLC - $90.98M in MANE purchases and sales in the last 12 months
- Ugur Sahin - $84.23M in BNTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Amy Moss Trombly?
Amy Moss Trombly is a corporate insider, tracked as Chief Executive Officer of Sonoma Pharmaceuticals, Inc. (SNOA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Amy Moss Trombly last file a Form 4?
The most recent primary Form 4 on record is dated 10 July 2026, one of 2 filings going back to 2026.